ABSTRACT
Statement of problem. Dental implants are susceptible to early failure when placed in patients
diagnosed with type 2 diabetes mellitus. The osteoinductive potential of insulin-like growth
factor-1 (IGF-1) has been widely investigated in animals with type 2 diabetes mellitus, but
studies investigating the osteoinductive potential of IGF-1 around dental implants in patients
diagnosed with type 2 diabetes mellitus are lacking.
Purpose. This randomized controlled trial was conducted to assess the osteogenic efficacy of
poly(lactide-co-glycolide)e (PLGA) encapsulated IGF-1 microspheres around dental implants
placed in patients diagnosed with type 2 diabetes mellitus.
Material and methods. A split-mouth, randomized controlled trial was conducted in 10
participants diagnosed with type 2 diabetes mellitus and with bilaterally missing mandibular
posterior teeth. The 20 sites were randomly allotted to receive the PLGA encapsulated IGF-1 or
placebo microspheres followed by the placement of Ø3.8×11-mm implants. Osteoblastic activity
was quantitatively assessed with bone scintigraphy scanning on the thirtieth, sixtieth, and 90th
day after implant placement. The Shapiro-Wilks test was used to analyze the normality of data,
followed by the independent t test to compare the experimental and placebo groups. Intragroup
comparison was performed by using repeated-measures ANOVA and the post hoc Bonferroni
test (a=.05).
Results. Statistical analysis revealed that the mean osteoblastic activity was higher in the
experimental group which received the PLGAeencapsulated IGF-1 than in the placebo group at
the 30th, 60th, and 90th day after implant placement (P.001).
Conclusions. This randomized controlled trial indicated that the PLGAeencapsulated sustained
release of IGF-1 microspheres enhanced the process of osseointegration in patients diagnosed
with type 2 diabetes mellitus until the 90th day after implant placement. (J Prosthet Dent
2021;)
